Immuneering (NASDAQ:IMRX) Shares Down 0.9% - Here's What Happened

Key Points

• Immuneering shares fell 0.9% to $4.57 in midday trading, with volume of approximately 624,000 shares. The stock remains below its 50-day and 200-day moving averages.
• Analyst sentiment is mixed but leans positive, with a consensus “Buy” rating and an average price target of $17.50; UBS has set a $14 target.
• Immuneering reported a quarterly loss of $0.27 per share, missing estimates by $0.01, while institutional investors own approximately 67.65% of the company.

Immuneering Corporation (NASDAQ:IMRX - Get Free Report)'s stock price fell 0.9% on Thursday . The stock traded as low as $4.47 and last traded at $4.57. 623,957 shares traded hands during mid-day trading, an increase of 0% from the average daily volume of 621,096 shares. The stock had previously closed at $4.61.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on IMRX shares. Chardan Capital upgraded shares of Immuneering to a "strong-buy" rating in a research report on Monday, August 3rd. Wall Street Zen downgraded shares of Immuneering from a "hold" rating to a "sell" rating in a report on Monday, July 20th. Weiss Ratings reissued a "sell (d-)" rating on shares of Immuneering in a research note on Wednesday, June 24th. UBS Group set a $14.00 target price on Immuneering in a report on Thursday, August 6th. Finally, Oppenheimer reaffirmed an "outperform" rating on shares of Immuneering in a report on Monday, June 1st. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $17.50.

Immuneering Price Performance

The stock's fifty day moving average is $4.83 and its 200-day moving average is $4.99. The stock has a market cap of $295.68 million, a PE ratio of -4.39 and a beta of 0.40.

Immuneering (NASDAQ:IMRX - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.01). On average, sell-side analysts expect that Immuneering Corporation will post -1.09 EPS for the current fiscal year.

Institutional Trading of Immuneering

Several institutional investors have recently made changes to their positions in IMRX. Geode Capital Management LLC grew its position in Immuneering by 2.0% in the second quarter. Geode Capital Management LLC now owns 230,275 shares of the company's stock worth $776,000 after acquiring an additional 4,458 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in shares of Immuneering in the 4th quarter valued at $33,000. Southport Management L.L.C. boosted its stake in Immuneering by 1.8% during the fourth quarter. Southport Management L.L.C. now owns 277,501 shares of the company's stock worth $1,826,000 after buying an additional 5,000 shares during the period. Dimensional Fund Advisors LP boosted its stake in Immuneering by 46.4% during the third quarter. Dimensional Fund Advisors LP now owns 19,562 shares of the company's stock worth $137,000 after buying an additional 6,196 shares during the period. Finally, LPL Financial LLC increased its position in shares of Immuneering by 30.0% during the fourth quarter. LPL Financial LLC now owns 29,125 shares of the company's stock valued at $192,000 after acquiring an additional 6,725 shares during the last quarter. Hedge funds and other institutional investors own 67.65% of the company's stock.

Immuneering Company Profile

Immuneering Nasdaq: IMRX is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering's machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company's AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company's lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.